These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6031262)

  • 21. Effects of 3,4-dimethoxyphenylethylamine in man.
    Hollister LE; Friedhoff AJ
    Nature; 1966 Jun; 210(5043):1377-8. PubMed ID: 5963772
    [No Abstract]   [Full Text] [Related]  

  • 22. Some observations on the behavioural effects of hallucinogenic drugs on rats: potentiation by two drugs affecting monoamine metabolism.
    Tonge SR; Leonard BE
    Arch Int Pharmacodyn Ther; 1972 Jan; 195(1):168-76. PubMed ID: 5010826
    [No Abstract]   [Full Text] [Related]  

  • 23. Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors.
    Andén NE; Corrodi H; Fuxe K; Meek JL
    Eur J Pharmacol; 1974 Feb; 25(2):176-84. PubMed ID: 4435021
    [No Abstract]   [Full Text] [Related]  

  • 24. Similarities and differences between mescaline, lysergic acid diethylamide-25 (LSD) and d-amphetamine on various components of fixed interval responding in the rat.
    Tilson HA; Sparber SB
    J Pharmacol Exp Ther; 1973 Feb; 184(2):376-84. PubMed ID: 4688175
    [No Abstract]   [Full Text] [Related]  

  • 25. Mescaline: no tolerance to excitatory effects.
    Bridger WH; Mandel IJ; Stoff DM
    Biol Psychiatry; 1973 Oct; 7(2):129-38. PubMed ID: 4748845
    [No Abstract]   [Full Text] [Related]  

  • 26. Amphetamine injections into the nucleus accumbens affect neither acquisition/expression of conditioned fear nor baseline startle response.
    Schwienbacher I; Fendt M; Schnitzler HU
    Exp Brain Res; 2005 Jan; 160(4):538-44. PubMed ID: 15650891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antianxiety agents and emotional behavior, an information processing analysis.
    Morris MD; Gebhart GF
    Prog Neuropsychopharmacol; 1981; 5(3):219-40. PubMed ID: 6115435
    [No Abstract]   [Full Text] [Related]  

  • 28. An economical screen for phenethylamine-type hallucinogens: mouse ear scratching.
    Yim GK; Prah TE; Pfister WR; Nichols DE
    Commun Psychopharmacol; 1979; 3(3):173-8. PubMed ID: 574070
    [No Abstract]   [Full Text] [Related]  

  • 29. Cerebral synaptic transmission and behavioral effects of dimethoxyphenylethylamine: a potential psychotogen.
    Vacca L; Fujimori M; Davis SH; Marrazzi AS
    Science; 1968 Apr; 160(3823):95-6. PubMed ID: 4296006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity relationship studies on mescaline. II. Tolerance and cross-tolerance between mescaline and its analogues in the rat.
    Smythies JR; Sykes EA; Lord CP
    Psychopharmacologia; 1966; 9(5):434-46. PubMed ID: 5998418
    [No Abstract]   [Full Text] [Related]  

  • 31. Fear-potentiated startle and light-enhanced startle models in drug discovery.
    Groenink L; Bijlsma EY; Olivier B
    Curr Protoc Pharmacol; 2008 Jun; Chapter 5():Unit5.48. PubMed ID: 22294228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationship studies on mescaline. 3. The influence of the methoxy groups.
    Smythies JR; Bradley RJ; Johnston VS; Benington F; Morin RD; Clark LC
    Psychopharmacologia; 1967; 10(5):379-87. PubMed ID: 5588333
    [No Abstract]   [Full Text] [Related]  

  • 33. Involvement of pertussis toxin sensitive G-proteins in conditioned fear-potentiated startle: possible involvement of the amygdala.
    Melia KR; Falls WA; Davis M
    Brain Res; 1992 Jul; 584(1-2):141-8. PubMed ID: 1515934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Influence of mescaline and of lysergic acid diethylamide (LSD-25) on the development of primary and secondary conditioned avoidance reflexes in rats].
    MAFFII G
    Farmaco Sci; 1959 Jul; 14():503-15. PubMed ID: 13853753
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of mescaline, amphetamine and four-ring substituted amphetamine derivatives on spontaneous brain electrical activity in the cat.
    Fairchild MD; Alles GA; Jenden DJ; Mickey MR
    Int J Neuropharmacol; 1967 May; 6(3):151-67. PubMed ID: 6037524
    [No Abstract]   [Full Text] [Related]  

  • 36. Extract of Ginkgo biloba EGb 761 facilitates fear conditioning measured by fear-potentiated startle.
    Yang YL; Su YW; Ng MC; Chang CL; Lu KT
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):145-50. PubMed ID: 15936528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral consequences of prenatal exposure to the organophosphate insecticide sumithion.
    Lehotzky K; Szeberenyi MJ; Kiss A
    Neurotoxicol Teratol; 1989; 11(3):321-4. PubMed ID: 2755428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of plasma from schizophrenics to potentiate the effects of 3,4-dimethoxyphenylethylamine on rats and mice.
    Masur J; Breda JB; Bueno OF; Carlini EA
    Arch Int Pharmacodyn Ther; 1969 May; 179(1):56-64. PubMed ID: 5348399
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of amygdaloid dopamine D2 receptors impairs emotional learning measured with fear-potentiated startle.
    Greba Q; Gifkins A; Kokkinidis L
    Brain Res; 2001 Apr; 899(1-2):218-26. PubMed ID: 11311883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiological disposition of beta-phenylethylamine, 2,4,5-trimethoxyphenylethylamine, 2,3,4,5,6-pentamethoxyphenylethylamine and beta-hydroxymescaline in rat brain, liver and plasma.
    Cohen I; Fischer JF; Vogel WH
    Psychopharmacologia; 1974 Mar; 36(1):77-84. PubMed ID: 4838506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.